FARN Share Price Performance
UK£0
-2.23 (-100.00%)
Price UK£0
Fair ValueUK£10.01
Share Pricen/a
Faron Pharmaceuticals Oy Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
FARN Community Narratives
AN
Fair Value
·Fair Value UK£10.01 95.9% undervalued intrinsic discount
Combination Immunotherapies In High Risk Cancers Will Support A Stronger Long Term Outlook
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Combination Immunotherapies In High Risk Cancers Will Support A Stronger Long Term Outlook
Catalysts About Faron Pharmaceuticals Oy Faron Pharmaceuticals Oy is a clinical stage biotech company focused on developing bexmarilimab in combination with hypomethylating agents for high risk myelodysplastic syndrome and other hard to treat cancers. What are the underlying business or industry changes driving this perspective?Read more
AN
UK£10.01
95.9% undervalued intrinsic discount
Fair Value
Profit Margin
32.59%
Future PE
206.7x
Price in 2029
UK£12.46
Trending Discussion
Recently Updated Narratives
AN
Combination Immunotherapies In High Risk Cancers Will Support A Stronger Long Term Outlook
Fair Value: UK£10.01 95.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Faron Pharmaceuticals Oy Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Aug 26, 2026
- -0.14
- 0%
- 0%
- -132.2%
About FARN
- Founded
- 2003
- Employees
- 33
- CEO
- WebsiteView website
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
